Stock Scorer

Summit Therapeutics Inc. (SMMT)

Summit Therapeutics Inc. reported revenue of 0 USD for the quarter ending 31 December 2024.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q4 '24 · ending 31 December 2024 0 —
Operating Income Q4 '24 · ending 31 December 2024 -65.6M —
Net Income Q2 '26 · ending 30 June 2026 -215.7M —
Operating Cash Flow Q2 '26 · ending 30 June 2026 -141.1M —
Free Cash Flow Q2 '26 · ending 30 June 2026 -142M —
Shares Outstanding Q2 '26 · ending 30 June 2026 778.2M +5.4%
EPS Q2 '26 · ending 30 June 2026 -1.11 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20242024-12-31 0-226M-221.3M-142.2M
20232023-12-31 0-609.6M-614.9M-76.9M
20222022-12-31 705K-72.1M-78.8M-42.2M
20212021-12-31 1.8M-86.2M-88.6M-72.9M
20202020-12-31 860K-53.2M-52.7M-48.5M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q4 '242024-12-310
Q3 '242024-09-300
Q4 '232023-12-310
Q3 '232023-09-300
Q2 '232023-06-300
Q1 '232023-03-310
Q4 '222022-12-310
Q3 '222022-09-30220K
Q2 '222022-06-30235K
Q1 '222022-03-31250K
Q4 '212021-12-31251K
Q3 '212021-09-301.3M
Q2 '212021-06-3057K
Q1 '212021-03-31192K
Q4 '202020-12-31185K
Q3 '202020-09-30181K
Q2 '202020-06-30170K
Q1 '202020-03-31324K
Q3 '192019-09-30148K
Q2 '192019-06-30156K

Operating Income Quarterly

PeriodEndingOperating Income
Q4 '242024-12-31-65.6M
Q3 '242024-09-30-58.4M
Q2 '242024-06-30-59.6M
Q1 '242024-03-31-42.4M
Q4 '232023-12-31-36.2M
Q3 '232023-09-30-20.5M
Q2 '232023-06-30-15.8M
Q1 '232023-03-31-537.2M
Q4 '222022-12-31-20.3M
Q3 '222022-09-30-16.9M
Q2 '222022-06-30-12.7M
Q1 '222022-03-31-22.2M
Q4 '212021-12-31-26M
Q3 '212021-09-30-19.5M
Q2 '212021-06-30-23.7M
Q1 '212021-03-31-16.9M
Q4 '202020-12-31-11.6M
Q3 '202020-09-30-16.9M
Q2 '202020-06-30-15.4M
Q1 '202020-03-31-9.3M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-215.7M
Q1 '262026-03-31-189.4M
Q4 '252025-12-31-219.2M
Q3 '252025-09-30-231.8M
Q2 '252025-06-30-565.7M
Q1 '252025-03-31-62.9M
Q4 '242024-12-31-61.2M
Q3 '242024-09-30-56.3M
Q2 '242024-06-30-60.4M
Q1 '242024-03-31-43.5M
Q4 '232023-12-31-36.6M
Q3 '232023-09-30-21.3M
Q2 '232023-06-30-14.7M
Q1 '232023-03-31-542.4M
Q4 '222022-12-31-19.2M
Q3 '222022-09-30-21.4M
Q2 '222022-06-30-16.8M
Q1 '222022-03-31-21.4M
Q4 '212021-12-31-27.1M
Q3 '212021-09-30-19.6M

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-141.1M
Q1 '262026-03-31-122.3M
Q4 '252025-12-31-101.9M
Q3 '252025-09-30-93.1M
Q2 '252025-06-30-66.7M
Q1 '252025-03-31-61.2M
Q4 '242024-12-31-48.7M
Q3 '242024-09-30-30.3M
Q2 '242024-06-30-33M
Q1 '242024-03-31-30.1M
Q4 '232023-12-31-19.5M
Q3 '232023-09-30-14.9M
Q2 '232023-06-30-29.3M
Q1 '232023-03-31-13.1M
Q4 '222022-12-315.2M
Q3 '222022-09-30-8.6M
Q2 '222022-06-30-19.2M
Q1 '222022-03-31-19M
Q4 '212021-12-31-9.2M
Q3 '212021-09-30-23.6M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-30-142M
Q1 '262026-03-31-122.5M
Q4 '252025-12-31-102.1M
Q3 '252025-09-30-93.2M
Q2 '252025-06-30-66.7M
Q1 '252025-03-31-61.6M
Q4 '242024-12-31-48.7M
Q3 '242024-09-30-30.4M
Q2 '242024-06-30-33.1M
Q1 '242024-03-31-30.1M
Q4 '232023-12-31-19.5M
Q3 '232023-09-30-14.9M
Q2 '232023-06-30-29.3M
Q1 '232023-03-31-13.2M
Q4 '222022-12-315.2M
Q3 '222022-09-30-8.6M
Q2 '222022-06-30-19.5M
Q1 '222022-03-31-19.4M
Q4 '212021-12-31-9.3M
Q3 '212021-09-30-23.6M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-30778.2M
Q1 '262026-03-31775.5M
Q3 '252025-09-30743.4M
Q2 '252025-06-30742.6M
Q1 '252025-03-31738.1M
Q3 '242024-09-30726.7M
Q2 '242024-06-30707.9M
Q1 '242024-03-31701.8M
Q3 '232023-09-30697.7M
Q2 '232023-06-30697.7M
Q1 '232023-03-31378.2M
Q3 '222022-09-30208.9M
Q2 '222022-06-30140.1M
Q1 '222022-03-31140M
Q3 '212021-09-3099M
Q2 '212021-06-3092.1M
Q1 '212021-03-3182.8M
Q3 '202020-09-3067.2M
Q2 '202020-06-3067.2M
Q1 '202020-03-3167.2M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-30-1.11
Q1 '262026-03-31-1.59
Q4 '252025-12-31-1.44
Q3 '252025-09-30-1.25
Q2 '252025-06-30-1.02
Q1 '252025-03-31-0.35
Q4 '242024-12-31-0.32
Q3 '232023-09-30-1.52
Q2 '232023-06-30-1.59
Q1 '232023-03-31-1.69
Q4 '222022-12-31-0.41
Q3 '222022-09-30-0.37
Q2 '222022-06-30-0.47
Q1 '222022-03-31-0.62
Q4 '212021-12-31-0.68
Q3 '212021-09-30-0.86
Q2 '212021-06-30-0.92
Q1 '212021-03-31-0.88
Q4 '202020-12-31-0.76